AH
NDRM

Andreas Halvorsen’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Andreas Halvorsen’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-708,898
Closed -$21.2M – 74
2017
Q2 		$21.2M Buy
+708,898
New +$18.4M 0.14% 53

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $1.08B AUM 105.75% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.72B AUM 70.66% 1-Year Est. Return

Andreas Halvorsen's NDRM Position: Q3 2017 in Review

Andreas Halvorsen sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 708,898 shares — an estimated $21.2M sold.

Andreas Halvorsen first reported a position in NDRM in Q2 2017 and held it in 1 quarter. The position peaked at $21.2M in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Andreas Halvorsen reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Andreas Halvorsen sold 708,898 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $21.2M.
  • Andreas Halvorsen first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2017 and held it in 1 quarter.
  • Andreas Halvorsen's NeuroDerm Ltd. Ordinary Shares position peaked at $21.2M in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Viking Global Investors's 13F filing for Q3 2017, filed 14 Nov 2017.